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Abstract
The clinical characteristics and risk factors for 28-day mortality in
120 patients with solid tumours with Acinetobacter nosocomialis
bacteraemia were retrospectively analysed. Eighty-one patients
(67.5%) had advanced-stage cancer. Most of the bacteraemia
(37.5%) did not have an identiﬁed source. The bacteraemia epi-
sodes developed at a median of 15 days after hospitalization, and
most during a non-neutropenic period (97.5%). Although only half
of the patients received appropriate antimicrobial therapy, the
mortality was relatively low (11.7%). High Pitt bacteraemia score
and receipt of chemotherapy within the month before bactera-
emia onset were independently associated with 28-day mortality.
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Acinetobacter baumannii (genomic species 2), Acinetobacter pittii
(genomic species 3) and Acinetobacter nosocomialis (genomic
species 13TU) are the three most clinically relevant Acineto-
bacter species[1–3]. They are not differentiated by the phe-
notypical tests commonly used in clinical microbiological
laboratories and are grouped together as A. baumannii com-
plex (ABC) [4].
ABC has increasingly caused bacteraemia in patients
with solid tumours [4–6]. It was recently shown that the
Acinetobacter species belonging to ABC differ in resistance
pattern, resistance mechanism and probably pathogenesis
[2,7,8]. Therefore, these species should be investigated
separately. Previous reports have indicated that A. nosocom-
ialis is the most common species that causes Acinetobacter
bacteraemia in patients with solid tumours [2,4]. Details of
patients with A. nosocomialis have not been described. In
this study, we analysed the records of patients with solid
tumours who had A. nosocomialis bacteraemia to determine
their clinical characteristics and assess risk factors for 28-
day mortality.
The study was conducted between 2000 and 2008 at Tai-
pei Veterans General Hospital (TVGH), a 2900-bed tertiary
medical centre in Taiwan. This study was approved by the
hospital’s institutional review board. The patients with solid
tumours with A. nosocomialis bacteraemia were included if
they were older than 18 years of age. The clinical data were
collected retrospectively from patient medical records, and
were deﬁned as previously described [4]. Bacteria were phe-
notypically identiﬁed to ABC using the API ID 32GN system
or Vitek 2 system (both from bioMe´rieux, Marcy l’Etoile,
France). If multiple ABC isolates were obtained from the
same patient, only the ﬁrst isolate was tested. Acinetobacter
nosocomialis was identiﬁed to the species level using 16S–23S
ribosomal DNA intergenic spacer sequence analysis, as previ-
ously described [9]. Antimicrobial susceptibility testing was
performed using an agar dilution test according to the rec-
ommendation of the Clinical and Laboratory Standards Insti-
tute [10]. The source of infection was identiﬁed using the
deﬁnitions of the Centers for Disease Control and Preven-
tion [11]. Multidrug resistance was deﬁned as resistance to
at least one agent in each of three or more classes of antimi-
crobial agents, including b-lactam/b-lactamase inhibitor com-
binations, extended-spectrum cephalosporins, carbapenems,
aminoglycosides and ﬂuoroquinolones[12]. The statistical
package SPSS for Windows (Version 18; SPSS Inc., Chicago,
IL) was used for all data analyses. Chi-square tests with
Yates’ correction or Fisher’s exact tests were used to com-
pare categorical differences. Continuous variables were anal-
ysed using Mann–Whitney U tests or two-sample t tests. All
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p values were two-tailed and p <0.05 was considered statisti-
cally signiﬁcant. Variables with p <0.10 that were exhibited
by at least 10% of the patients in univariate analyses were
subsequently subjected to multivariate analyses to assess
independent risk factors for acquisition of multidrug-resistant
isolates and mortality.
A total of 120 patients were included. Their characteris-
tics are shown in Table 1. Colorectal cancer was the most
prevalent underlying tumour type and ten patients had dou-
ble cancers. About two-thirds of the patients were in an
advanced stage of cancer. Most of the patients did not have
neutropenia. Among the 22 patients undergoing major oper-
TABLE 1. Clinical characteristics of patients with solid tumours who survived or died within 28 days of Acinetobacter nosocomi-
alis bacteraemia onseta
Variables All (n = 120) Survivor (n = 106) Non-survivor (n = 14) pb
Demographic data
Age (years), mean ± SD 65.66 ± 14.09 65.92 ± 14.43 63.64 ± 11.35 0.571
Sex (male) 81 (67.5) 74 (69.8) 7 (50.0) 0.223
ICU admissionc 45 (37.5) 42 (39.6) 3 (21.4) 0.186
Pitt bacteraemia score 2.00 (1.00–4.75) 2.00 (1.00–4.00) 3.50 (2.00–6.25) 0.049
Length of stay (days) 38.00 (21.00–63.50) 43.50 (26.00–71.00) 21.50 (12.25–25.00) <0.01
Time between admission and culture-positive date (days) 15.00 (7.00–25.00) 15.00 (7.00–28.00) 15.00 (5.00–18.25) 0.177
Underlying diseases
Chemotherapy within 1 month before bacteraemia 37 (30.8) 28 (26.4) 9 (64.3) 0.010
Neutropeniad 3 (2.5) 3 (2.7) 0 (0) >0.99
Hypertension 29 (24.2) 26 (24.5) 3 (21.4) >0.99
Coronary arterial disease 12 (10.0) 11 (10.4) 1 (7.1) >0.99
Congestive heart failure 5 (4.2) 5 (4.7) 0 (0) >0.99
Cerebrovascular disease 16 (13.3) 12 (11.3) 4 (28.6) 0.092
Diabetes mellitus 23 (19.2) 20 (18.9) 3 (21.4) >0.99
Smoking 21 (17.5) 19 (17.9) 2 (14.3) >0.99
Chronic lung disease 14 (11.7) 14 (13.2) 0 (0) 0.368
Connective tissue disease 3 (2.5) 3 (2.8) 0 (0) >0.99
Steroid usee 13 (10.8) 13 (12.3) 0 (0) 0.359
Use of immunosuppressive agents 5 (4.2) 5 (4.7) 0 (0) >0.99
Liver cirrhosis 12 (10.0) 11 (10.4) 1 (7.1) >0.99
Alcoholism 11 (9.2) 9 (8.5) 2 (14.3) 0.616
Chronic renal disease 11 (9.2) 10 (9.4) 1 (7.1) >0.99
End-stage renal disease 4 (3.3) 4 (3.8) 0 (0) >0.99
Invasive procedures
Endotracheal intubation/tracheostomy 43 (35.8) 38 (35.8) 5 (35.7) 0.992
Central vascular device 57 (47.5) 49 (46.2) 8 (57.1) 0.442
Port-A implant 10 (8.3) 8 (7.5) 2 (14.3) 0.391
Major operation within 1 month 22 (18.3) 22 (20.8) 0 (0) 0.070
TPN 7 (5.8) 6 (5.7) 1 (7.1) 0.590
Underlying cancer type
Colon and rectal cancer 18 (15) 16 (15.1) 2 (14.3) >0.99
Oesophago-gastrointestinal cancer 17 (14.2) 16 (15.1) 1 (7.1) 0.689
Lung cancer 16 (13.3) 14 (13.2) 2 (14.3) >0.99
Head and neck cancer 15 (12.5) 13 (12.3) 2 (14.3) 0.687
Hepato-biliary cancer 10 (8.3) 9 (8.5) 1 (7.1) >0.99
Breast cancer 10 (8.3) 8 (7.5) 2 (14.3) 0.329
Brain tumour 10 (8.3) 9 (8.5) 1 (7.1) >0.99
Renal/bladder/prostate cancer 9 (7.5) 9 (8.5) 0 (0) 0.596
Gynaecological cancer 9 (7.5) 8 (7.5) 1 (7.1) >0.99
Pancreatic cancer 5 (4.2) 3 (2.8) 2 (14.3) 0.103
Miscellaneous 7 (5.8) 6 (5.7) 1 (7.1) 0.590
Advanced cancer status 81 (67.5) 69 (65.1) 12 (85.7) 0.143
Cancer with metastasis 54 (45.0) 46 (43.4) 8 (57.1) 0.331
Source of bacteraemia
Primary 45 (37.5) 41 (38.7) 4 (28.6) 0.463
Respiratory 36 (30.0) 30 (28.3) 6 (42.9) 0.264
Catheter-related 21 (17.5) 21 (19.8) 0 (0) 0.126
Intra-abdominal 8 (6.7) 5 (4.7) 3 (21.4) 0.050
Skin and soft tissue 6 (5.0) 6 (5.7) 0 (0) >0.99
Others 4 (3.3) 3 (2.8) 1 (7.1) 0.395
Polymicrobial bacteraemia 26 (21.7) 20 (18.9) 6 (42.9) 0.077
Multidrug resistant isolates 37 (30.8) 32 (30.2) 5 (35.7) 0.760
Appropriate antimicrobial therapy 60 (50.0) 55 (51.9) 5 (35.7) 0.255
SD, standard deviation; ICU, intensive care unit; TPN, total parenteral nutrition.
aData are median value (interquartile range) for continuous variables and number of cases (%) for categorical variables.
bp <0.05 is considered signiﬁcant.
cA stay in the ICU within the 2 weeks before the ﬁrst positive blood culture.
dAn absolute neutrophil count of <500 cells/mm3.
eUse of >10 mg prednisolone per day for >5 days in the 2 weeks before a bacteraemic episode.
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ations within the month preceding bacteraemia onset, most
(17; 77.3%) underwent surgery for primary tumour resec-
tion. In addition to solid tumours, most patients had co-
morbidities (84.2%) and many were treated with invasive
devices during bacteraemia episodes (69.2%). The median
duration between admission and bacteraemia onset was
15 days. The infection source was not identiﬁed in many of
the bacteraemia cases and these were considered to be pri-
mary bacteraemia (37.5%). Twenty-six patients (21.7%) had
polymicrobial bacteraemia, and the most common concomi-
tantly isolated pathogen was Pseudomonas aeruginosa (5/26,
19.2%), followed by Stenotrophomonas maltophilia (4/26,
15.3%). A total of 60 patients (50.0%) received appropriate
antimicrobial therapy. The antimicrobial susceptibilities of
the isolates are shown in Table 2. More than 80% of isolates
were susceptible to meropenem, imipenem, cefepime, ceftaz-
idime, ciproﬂoxacin and ampicillin/sulbactam. Thirty-seven
isolates had a multidrug-resistant phenotype. In multivariate
analysis, the independent factors associated with acquisition
of multidrug-resistant isolates were high Pitt bacteraemia
scores (OR, 1.35; 95% CI, 1.10–1.66, p 0.005), previous use
of anti-pseudomonal b-lactam/b-lactamase inhibitor (OR,
6.92; 95% CI, 1.25–38.22, p 0.027) or receipt of surgery
within 1 month before bacteraemia onset (OR, 6.01; 95%
CI, 1.88–19.22, p 0.003).
The 14-day and 28-day mortalities were 3.3% and 11.7%,
respectively. More survivors received appropriate antimicro-
bial therapy than non-survivors, but the difference did not
reach signiﬁcance (p 0.255). In multivariate analysis, high Pitt
bacteraemia score (OR, 1.62; 95% CI, 1.18–2.22, p 0.003)
and receipt of chemotherapy within the month before bac-
teraemia onset (OR, 12.68; 95% CI, 2.71–59.28, p 0.001)
were independently associated with 28-day mortality.
Acinetobacter nosocomialis should be considered as the
pathogen causing nosocomial bacteraemia in patients with
advanced cancer that do not have neutropenia. A study of
neutropenic and non-neutropenic cancer patients also
showed that Acinetobacter species were recovered from non-
neutropenic patients signiﬁcantly more often, whereas Escher-
ichia coli, Klebsiella spp. and P. aeruginosa were found signiﬁ-
cantly more often in neutropenic patients[13].
The mortality of A. nosocomialis bacteraemia among our
patients with solid tumours (11.7%) was comparable to those
described in other studies (15.6–16.7%) [1,2], but was
much lower than the mortality caused by A. baumannii bac-
teraemia (29.7–58.6%) [1,2,5]. It has been suggested that
A. nosocomialis has lower pathogenicity [1,2,7]. This might
explain the marginal effect of appropriate antimicrobial ther-
apy on mortality.
In our study, a high Pitt bacteraemia score was an inde-
pendent risk factor for mortality. This is consistent with a
previous study of patients with ABC bacteraemia [2,14].
Recent chemotherapy has been reported to be a factor asso-
ciated with increased mortality among cancer patients with
multidrug-resistant Enterobacteriaceae bacteraemia [15]. In
these patients, post-chemotherapy-related immunosuppres-
sion might have further reduced host defences that had
already been weakened by neoplastic disease.
In conclusion, A. nosocomialis is a nosocomial pathogen
causing bacteraemia in non-neutropenic patients with
advanced-stage solid tumours. High Pitt bacteraemia score
and receipt of chemotherapy within the month before bac-
teraemia onset are independent risk factors for mortality.
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TABLE 2. Antimicrobial susceptibil-
ity of Acinetobacter nosocomialis
recovered from blood samples
obtained from patients with solid
tumours who survived or died
within 28 days of bacteraemia onset
Antimicrobials








Ampicillin/sulbactam 99 (82.5) 87 (82.1) 12 (85.7) >0.99
Colistin 94 (78.3) 82 (77.4) 12 (85.7) 0.732
Ciproﬂoxacin 109 (90.0) 95 (89.6) 13 (92.9) >0.99
Gentamicin 80 (66.7) 70 (66.0) 10 (9.3) 0.772
Ceftriaxone 37 (30.8) 33 (31.1) 4 (28.6) >0.99
Ceftazidime 102 (85.0) 89 (84.0) 13 (92.9) 0.691
Cefoperazone 30 (25.0) 27 (25.5) 3 (21.4) 0.99
Cefepime 107 (89.2) 94 (88.7) 13 (92.9) >0.99
Piperacillin/tazobactam 92 (76.7) 80 (75.5) 12 (85.7) 0.516
Imipenem 100 (83.3) 87 (82.1) 13 (92.9) 0.461
Meropenem 108 (90.0) 94 (88.7) 14 (100.0) 0.356
ap <0.05 is considered signiﬁcant.
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